Chronic Kidney Disease

Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States.

Kidney Week 2022 focused on effectiveness of treatment for chronic kidney disease, health misinformation, and outcomes in chronic kidney disease, among other topics.

Lower estimated tubular secretion was found to be associated with a faster decline of estimated glomerular filtration rate (eGFR) but wasn’t associated with progression of chronic kidney disease or cardiovascular disease.

A retrospective study found roxadustat to be more effective in improving hemoglobin levels in patients who had with chronic kidney disease (CKD) compared with recombinant human erythropoietin.

Implantable cardioverter defibrillators (ICDs) were found to have a beneficial effect on mortality in patients with chronic kidney disease (CKD).

Prescriptions for treatment of atrial fibrillation (AF) and chronic kidney disease (CKD) have primarily been prescriptions for direct oral anticoagulants (DOACs), displacing warfarin as the primary treatment.

A cohort study found that chronic kidney disease (CKD) was associated with the development of abdominal aortic aneurysm, with risk increasing as CKD stage advanced.

Speaking with patients diagnosed with chronic kidney disease (CKD) about the burdens associated with care could help improve understanding of the disease and their communication with health care professionals.

Treatment with an angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker and sodium-glucose cotransporter-2 (SGLT2) inhibitor combination demonstrated better outcomes in kidney failure.

A new review has found that increased incidence of chronic kidney disease (CKD) may be seen among patients with nonalcoholic fatty liver disease.

The studies reviewed estimates of economic and humanistic impact on both patients with chronic kidney disease (CKD) as well as their caregivers.

Updated Kidney Disease: Improving Global Outcomes guidelines and a consensus report with the American Diabetes Association support the use of finerenone in certain patients who have chronic kidney disease (CKD) that may be linked to type 2 diabetes (T2D).

FDA advisers voted in favor of approving Ardelyx’s tenapanor for patients with chronic kidney disease on dialysis; US home births increased by about 12% between 2020 and 2021; surges in respiratory viruses, especially respiratory syncytial virus (RSV) among younger children are putting pediatric hospitals at capacity.

A prospective population-based cohort study found that glomerular filtration rate based on cystatin C was more sensitive and specific for cardiovascular disease (CVD) and mortality risks compared with glomerular filtration rate based on creatinine.

A systematic review found that alternative approaches to calculating estimated glomerular filtration rate (eGFR) were worth looking into to properly account for diversity in populations.

The author, the dean of the College of Ethnic Studies at California State University Los Angeles, says a Supreme Court ruling could upend insurance protections for patients with kidney diseases, disproportionately hurting those who are Black, Hispanic, Asian, and other diverse ethnicities.

The launch of the National Kidney Foundation’s first nationwide registry of patients with kidney disease could help link patient data with laboratory and clinical information.

A cross-sectional study found that severe anemia was common in patients with chronic kidney disease (CKD) and was associated with lower glomerular filtration rate (eGFR) and multiple adverse outcomes.

An increased risk of emergency department visits for patients with kidney disease was found when patients were exposed to extreme heat.

This study found that the recent change to remove race from the calculation of estimated glomerular filtration rate (eGFR) may incorrectly label potential donors who are Black as having chronic kidney disease (CKD).

A retrospective observational study found that there was a decline in health care services for patients with chronic kidney disease (CKD) during the early months of the COVID-19 pandemic.

A recent report found that 56% of patients from The Netherlands who underwent a kidney transplant were able to work and functioned well while working.

Genomic testing can benefit patients with chronic kidney disease (CKD) as more causative genes are identified and evidence for clinical utility is discovered.

A recent study found that patients with chronic kidney disease and atrial fibrillation are increasingly using direct oral anticoagulants.

A retrospective cohort study found that a drop in events signaling renal function decline during the COVID-19 pandemic could be associated with a decrease in fine particulate matter concentration.

Post-menopausal women who had dynapenic-abdominal obesity, determined by hand-grip strength and waist circumference, had a higher risk of chronic kidney disease (CKD) compared with controls.

Sarah Wells Kocsis, MBA, is co-author of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.” She spoke to The American Journal of Managed Care® about the findings of the report and how they can be incorporated into care for patients with chronic kidney disease (CKD).

Katherine R. Tuttle, MD, FASN, FACP, FNKF, a nephrologist from the University of Washington and Providence Health Care, discussed new consensus guidelines that call for the early use of sodium glucose cotransporter 2 (SGLT2) inhibitors, GLP-1 receptor agonists, and finerenone in the care of patients with both chronic kidney disease (CKD) and diabetes.

Sarah Wells Kocsis, MBA, is co-author of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.” She spoke to The American Journal of Managed Care® about the findings of the report and how they can be incorporated into care for patients with chronic kidney disease (CKD).

A recent study found that the largest Medicare Advantage plans pay large markups to large dialysis organizations, and these inflated payments could increase out-of-pocket expenses for patients.